Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | CXCR5 | P32302 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520679 | 0.96 | BCL2L1 (0.48) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL29493191 | 0.86 | CXCR5 (0.56) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL11814300 | 0.86 | BCL2L1 (0.55) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL783869 | 0.86 | CXCR5 (0.56) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL5755502 | 0.84 | CXCR5 (0.55) | BCL2L1BADCXCR5MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2398251 | 0.84 | CXCR5 (0.55) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL4570298 | 0.82 | BCL2L1 (0.52) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL1159789 | 0.82 | BCL2L1 (0.52) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL31359858 | 0.82 | BCL2L1 (0.52) | BCL2L1BADCXCR5MEN1KMT2A | |
| SCHEMBL3124135 | 0.82 | BCL2L1 (0.52) | BCL2L1BADCXCR5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | BCL2L1 2657/4885BAD 2060/4885CXCR5 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.